Filing Details

Accession Number:
0001725160-20-000052
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-03 17:57:29
Reporting Period:
2020-04-07
Accepted Time:
2020-12-03 17:57:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1725160 Zentalis Pharmaceuticals Inc. ZNTL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1808098 Michael David Johnson C/O Zentalis Pharmaceuticals, Inc.
530 Seventh Avenue, Suite 2201
New York NY 10018
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-04-07 4,000 $18.00 114,648 No 4 P Direct
Common Stock Disposition 2020-12-02 1,600 $49.80 113,048 No 4 S Direct
Common Stock Disposition 2020-12-02 3,868 $50.82 109,180 No 4 S Direct
Common Stock Disposition 2020-12-02 4,603 $51.61 104,577 No 4 S Direct
Common Stock Disposition 2020-12-02 2,825 $52.72 101,752 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
  2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.30 to $50.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.32 to $51.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.32 to $52.26. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.39 to $53.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.